Trading Report: The Exact Sciences Corp. (EXAS) Position Boosted by Nationwide Fund Advisors

The Exact Sciences Corp. (EXAS) Position Boosted by Nationwide Fund Advisors

Nationwide Fund Advisors boosted its position in shares of Exact Sciences Corp. (NASDAQ:EXAS) by 2.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 63,002 shares of the company’s stock after buying an additional 1,555 shares during the period. Nationwide Fund Advisors owned 0.06% of Exact Sciences Corp. worth $772,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. BlackRock Institutional Trust Company N.A. raised its position in shares of Exact Sciences Corp. by 0.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,337,794 shares of the company’s stock valued at $15,757,000 after buying an additional 13,009 shares in the last quarter. UBS Asset Management Americas Inc. raised its position in shares of Exact Sciences Corp. by 2.8% in the first quarter. UBS Asset Management Americas Inc. now owns 1,186,519 shares of the company’s stock valued at $7,997,000 after buying an additional 32,579 shares in the last quarter. Squarepoint Ops LLC raised its position in shares of Exact Sciences Corp. by 106.3% in the first quarter. Squarepoint Ops LLC now owns 143,200 shares of the company’s stock valued at $965,000 after buying an additional 73,800 shares in the last quarter. Carl Domino Inc bought a new position in shares of Exact Sciences Corp. during the second quarter valued at $306,000. Finally, Creative Planning raised its position in shares of Exact Sciences Corp. by 227.0% in the second quarter. Creative Planning now owns 196,440 shares of the company’s stock valued at $2,406,000 after buying an additional 136,360 shares in the last quarter. 86.88% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Corp. (NASDAQ:EXAS) traded up 1.38% during mid-day trading on Friday, hitting $15.48. 2,862,534 shares of the company’s stock were exchanged. The stock’s market capitalization is $1.68 billion. Exact Sciences Corp. has a 52 week low of $4.67 and a 52 week high of $22.80. The firm has a 50 day moving average of $19.11 and a 200 day moving average of $13.73.

Exact Sciences Corp. (NASDAQ:EXAS) last released its earnings results on Wednesday, October 26th. The company reported ($0.36) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.06. The firm earned $28.10 million during the quarter, compared to analysts’ expectations of $25.24 million. Exact Sciences Corp. had a negative net margin of 216.45% and a negative return on equity of 55.44%. The business’s quarterly revenue was up 122.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.45) EPS. Equities analysts forecast that Exact Sciences Corp. will post ($1.75) earnings per share for the current fiscal year.

Several brokerages have weighed in on EXAS. Benchmark Co. raised their price objective on shares of Exact Sciences Corp. from $14.00 to $17.00 and gave the stock a “hold” rating in a report on Wednesday. Robert W. Baird reissued an “outperform” rating and set a $18.00 price objective on shares of Exact Sciences Corp. in a report on Sunday, July 31st. William Blair reissued an “outperform” rating and set a $29.00 price objective on shares of Exact Sciences Corp. in a report on Friday, July 15th. BTIG Research reissued a “buy” rating and set a $20.00 price objective on shares of Exact Sciences Corp. in a report on Sunday, July 31st. Finally, Goldman Sachs Group Inc. raised their price objective on shares of Exact Sciences Corp. from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, August 15th. Seven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Exact Sciences Corp. has an average rating of “Hold” and a consensus price target of $18.27.

In related news, Director Lionel Sterling bought 5,000 shares of the business’s stock in a transaction that occurred on Thursday, September 1st. The stock was purchased at an average cost of $18.10 per share, for a total transaction of $90,500.00. Following the purchase, the director now directly owns 121,247 shares in the company, valued at $2,194,570.70. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Katherine S. Zanotti bought 3,380 shares of the business’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were bought at an average price of $17.93 per share, with a total value of $60,603.40. Following the completion of the purchase, the director now owns 105,927 shares in the company, valued at $1,899,271.11. The disclosure for this purchase can be found here. Corporate insiders own 5.60% of the company’s stock.

About Exact Sciences Corp.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.

Related posts

Leave a Comment